Medpace (NASDAQ:MEDP) Shares Gap Down - What's Next?

Key Points

• Medpace Holdings, Inc. shares gapped down from a previous close of $543.90 to open at $525.75, with the last trade recorded at $529.33.
• Analyst ratings are mixed, with two analysts giving a Buy rating, twelve assigning Hold, and three rating it as Sell, leading to a consensus rating of "Reduce" and an average price target of $422.27.
• Following strong quarterly earnings that exceeded expectations, Medpace's FY 2025 EPS guidance is set at 13.760-14.53, with analysts predicting 12.29 EPS for the current fiscal year.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $543.90, but opened at $525.75. Medpace shares last traded at $529.33, with a volume of 48,470 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MEDP. Deutsche Bank Aktiengesellschaft upped their price objective on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and raised their price objective for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Barclays raised their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Zacks Research downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 22nd. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Trading Down 1.2%

The company has a market cap of $15.09 billion, a P/E ratio of 39.93, a PEG ratio of 3.24 and a beta of 1.40. The business's fifty day moving average is $471.53 and its 200 day moving average is $364.83.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace's revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group increased its stake in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. increased its stake in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares in the last quarter. Employees Retirement System of Texas bought a new position in shares of Medpace during the second quarter valued at approximately $36,000. Finally, IFP Advisors Inc grew its holdings in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company's stock valued at $61,000 after buying an additional 134 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.